U.S. Insurance Stock News

PDD Holdings recently expanded its leadership structure by appointing Co-CEO and founding member Jiazhen Zhao as Co-Chairman of the Board alongside Lei Chen, while also naming Mi Wang as Senior Vice President of Engineering and Jiong Li as Financial Director. These appointments bring operational, engineering, and financial leaders with deep company and industry experience into more influential roles, potentially shaping how PDD balances growth investments, technology development, and...

Frontier Group Holdings, Inc. has appointed President James G. Dempsey as Interim CEO effective December 15, 2025, with longtime CEO Barry L. Biffle transitioning to an advisory role through year-end. Dempsey’s progression from CFO to President and now Interim CEO, backed by experience at Ryanair and PricewaterhouseCoopers, signals continuity rooted in deep airline and financial expertise. We’ll now explore how Dempsey’s interim appointment and his operational and financial background could...

CRISPR Therapeutics (CRSP) just gave investors a fresh update on zugo cel, its off the shelf CAR T therapy, highlighting strong early responses, clean safety signals, and a new combo study with Eli Lilly. See our latest analysis for CRISPR Therapeutics. The upbeat zugo cel update comes after a choppy stretch where CRISPR Therapeutics’ 1 month share price return of 10.65 percent and year to date share price return of 36.88 percent contrast with a still deeply negative 5 year total shareholder...

Check Point Software Technologies (CHKP) has been quietly outpacing the broader cybersecurity space this month, with shares up about 3% despite a mixed backdrop for tech and security names. See our latest analysis for Check Point Software Technologies. That steady 2.13% year to date share price return, alongside a 50.92% three year total shareholder return, suggests Check Point’s cybersecurity story is more about enduring compounding than short term excitement. Momentum has cooled slightly...

In December 2025, Zenas BioPharma was added to the NASDAQ Biotechnology Index and filed a US$45.59 million shelf registration tied to an employee stock ownership plan, as investors focused on upcoming Phase 3 INDIGO trial results for its lead drug obexelimab in IgG4-Related Disease. The convergence of index inclusion, fresh capital flexibility, and obexelimab’s pivotal data approaching has put Zenas at the center of growing analyst and investor attention around IgG4-RD therapeutics. Against...

In August 2025, the U.S. District Court for the Middle District of North Carolina granted NeoGenomics summary judgment, invalidating Natera's asserted patents and dismissing Natera's claims with prejudice, and Natera has since voluntarily withdrawn its appeal, leading NeoGenomics to drop its cross-appeal. This outcome removes a key intellectual property overhang for NeoGenomics' RaDaR MRD platform and broader oncology test menu, clarifying legal risk around future product development. We...

TKO Group Holdings (TKO) just wrapped an $800 million accelerated share repurchase and rolled out a fresh plan to buy back another $174 million, a capital return signal that investors are clearly taking seriously. See our latest analysis for TKO Group Holdings. The buybacks come as TKO trades near record highs at $217.98, with a roughly 20% 1 month share price return contributing to a strong year to date share price gain. This suggests momentum is still building as investors reassess its...

In the past quarter, London-based Decagon Asset Management and Sand Grove Capital Management each initiated sizeable positions in CyberArk Software, making the identity security provider one of the largest holdings in both firms’ U.S. equity portfolios. The fact that two separate London hedge funds independently concentrated so much capital in CyberArk highlights growing institutional conviction in its subscription-driven, recurring revenue model. Next, we’ll examine how this concentrated...

Pulse Biosciences (PLSE) just cleared a key regulatory hurdle, with the FDA approving its Investigational Device Exemption for a pivotal U.S. study of the nPulse Cardiac Catheter Ablation System in paroxysmal atrial fibrillation. See our latest analysis for Pulse Biosciences. The FDA green light seems to have reminded investors what is at stake, with a 1 week share price return of 4.21 percent and a 1 month share price return of 13.52 percent standing in contrast to a weaker year to date...

Varonis Systems (VRNS) is back in the spotlight after its third quarter 2025 earnings miss, a sharp drop in term license subscription revenue, and a cut to full year ARR guidance triggered a steep selloff. See our latest analysis for Varonis Systems. That reset has been brutal for recent holders, with the 90 day share price return at around negative 43 percent and 1 year total shareholder return down roughly 26 percent, even though the 3 year total shareholder return remains positive and...

Entegris (ENTG) is back in the spotlight after Goldman Sachs cut the stock to Sell, arguing margins and sector positioning look challenged even as management leans into a more upbeat long term growth story. See our latest analysis for Entegris. The downgrade comes after a choppy stretch for Entegris, with a 1 month share price return of 13.87 percent but a negative year to date share price return and a 1 year total shareholder return of minus 15.62 percent. This suggests momentum is still...

Amylyx Pharmaceuticals recently reported positive early safety data from its AMX0114 ALS program and moved to expand the Phase 1 LUMINA trial, while director Karen Firestone purchased US$100,845 of company stock to increase her personal stake. Together, the encouraging AMX0114 safety readout and insider buying highlight both the scientific potential of Amylyx’s pipeline and visible confidence from its leadership. We’ll now examine how the early AMX0114 safety results shape Amylyx...

SES AI (NYSE:SES) just put two weighty catalysts on the table: a Korea based manufacturing collaboration aimed at NDAA compliant drone batteries, and its upcoming Battery World update on AI driven cell technology and capacity. See our latest analysis for SES AI. Those drone and AI battery headlines are landing against a backdrop where SES AI’s share price return has quietly shifted higher, with a roughly 10 percent 3 month share price return and a 1 year total shareholder return near 190...

Ryder System has announced a leadership transition, with long-tenured CEO and Chairman Robert E. Sanchez set to retire on March 31, 2026, and President and COO John J. Diez scheduled to assume the chief executive role and join the board on the same date. Alongside this CEO succession, the board is evolving with the planned retirement of director Abbie Smith and the addition of former Southwest Airlines CFO Tammy Romo, whose financial oversight experience and committee roles may influence...

Northwest Natural Holding (NWN) just paired a 200 million long term bond raise with a planned handoff in its top legal seat, a combination that quietly reshapes both its balance sheet and governance profile. See our latest analysis for Northwest Natural Holding. Those moves come after a solid run for the stock, with a year-to-date share price return of about 19 percent and a one-year total shareholder return close to 25 percent, suggesting momentum has been quietly building as investors...

Bilibili (BILI) just picked up an upgrade to a Zacks Rank of 2, Buy, after analysts sharply raised full year earnings estimates, a shift that helps explain the stock’s strong year to date rally. See our latest analysis for Bilibili. The upgrade lands after a volatile stretch in the stock, with a robust 44.60% year to date share price return contrasting with a softer 29.08% one year total shareholder return. This suggests that momentum is rebuilding as earnings expectations reset. If this kind...

Integer Holdings (ITGR) is back in the spotlight after a wave of securities fraud class actions, with shareholders alleging management oversold demand for its electrophysiology devices before cutting guidance and resetting growth expectations. See our latest analysis for Integer Holdings. The market reaction has been brutal, with the share price down roughly 40 percent year to date despite a solid multiyear total shareholder return. The recent bounce from $78.71 suggests any short term...

TechnipFMC (FTI) just landed a substantial EPCI contract from Eni for the Coral North FLNG project offshore Mozambique, a material win that adds visibility to future revenue and helps explain the recent strength in the stock. See our latest analysis for TechnipFMC. That Coral North award caps a run of positive catalysts for TechnipFMC, including the recent Gorgon Stage 3 Subsea 2.0 contract and ongoing high profile investor engagement. The stock has responded with a strong year to date share...

Globe Life (GL) just launched Globe Life Re Ltd. in Bermuda, a new reinsurance platform aimed at centralizing how the group shares and manages risk across its insurance affiliates. See our latest analysis for Globe Life. The move comes after a strong run in the stock, with a year to date share price return of about 27.9 percent and a one year total shareholder return of roughly 30.7 percent. This suggests momentum is building as investors reassess its growth and risk profile. If this kind of...

Earlier this week, Wells Fargo and other analysts raised their outlooks on Antero Midstream, while the company moved its funding mix toward newly issued Notes and away from legacy debt facilities. This combination of stronger analyst sentiment and a simplified capital structure has sharpened investor focus on how Antero Midstream intends to finance future growth and distributions. We’ll now examine how Antero Midstream’s shift toward Notes-based funding could influence its investment...

Signet Jewelers (SIG) has quietly become one of retail’s more interesting value stories, with the stock up about 12% this year but still giving back some gains over the past month and past 3 months. See our latest analysis for Signet Jewelers. At around $87.01 per share, Signet’s recent pullback, including a weaker 1 month share price return after a solid year to date share price gain, looks more like cooling momentum than a broken story, especially given its strong 5 year total shareholder...

Amcor plc has confirmed it will implement a previously approved 1-for-5 reverse stock split, effective after the close of trading on January 14, 2026, consolidating its approximately 2.30 billion outstanding ordinary shares into about 0.46 billion and proportionately adjusting authorized share capital, par value, CHESS Depositary Interests, and equity-based awards. The move simplifies Amcor's capital structure and lifts the per-share reference price, while cashing out fractional holdings and...

Invitation Homes (INVH) just gave income investors something to chew on, lifting its quarterly dividend by 3.4% to 0.30 dollars a share, with the new payout tied to a late December record date. See our latest analysis for Invitation Homes. The higher dividend lands at a time when Invitation Homes shares trade around 27.32 dollars, with a year to date share price return in negative territory but a modestly positive three year total shareholder return suggesting longer term momentum is still...

Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately sharpened the stock’s risk reward profile. See our latest analysis for Relay Therapeutics. The zovegalisib update lands after a sharp rebound in sentiment, with a roughly 97 percent 90 day share price return and a 104 percent one year total shareholder return, even though the five year total...